<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077085</url>
  </required_header>
  <id_info>
    <org_study_id>BSTEP</org_study_id>
    <nct_id>NCT05077085</nct_id>
  </id_info>
  <brief_title>Bezlotoxumab Versus FMT for Multiple Recurrent CDI</brief_title>
  <acronym>BSTEP</acronym>
  <official_title>New Treatment Strategy for Patients With Multiple Recurrent Clostridioides Difficile Infection With Bezlotoxumab as First Option</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OLVG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Center Haaglanden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to investigate whether a treatment strategy offering&#xD;
      bezlotoxumab before FMT in patients suffering from multiple recurrent CDI results in equal&#xD;
      efficacy compared with a treatment strategy with initial FMT. Strategy A includes&#xD;
      bezlotoxumab as ancillary treatment as first option, and FMT in case of failure. Option B&#xD;
      includes FMT as ancillary treatment as first option, and antibiotic treatment with&#xD;
      fidaxomicin in case of failure. A secondary objective is to provide a point estimate of&#xD;
      recurrence after bezlotoxumab for the treatment of multiple recurrent CDI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter open label randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global cure of the treatment strategy</measure>
    <time_frame>12 weeks (after rescue therapy if applicable)</time_frame>
    <description>Defined as cure without relapse of CDI within 12 weeks after completion of the treatment strategy in the study arm, i.e. after completion of secondary treatment in case of failure on initial treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Initial cure after treatment with bezlotoxumab or FMT</measure>
    <time_frame>2 days after end of treatment</time_frame>
    <description>Defined as cure after completion of the primary CDI treatment in the study arm. Initial cure is assessed at day 2 after end of treatment (EOT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence after initial treatment with bezlotoxumab or FMT</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as CDI relapse within 12 weeks after initial cure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained cure after initial treatment with bezlotoxumab or FMT</measure>
    <time_frame>12 weeks</time_frame>
    <description>Sustained cure is defined as cure without relapse of CDI within 12 weeks after completion of the initial treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Throughout the entire study all adverse events will be noted. After the final study procedure of the last patient, all adverse events will be categorized:&#xD;
Most likely related to ancillary CDI treatment (bezlotoxumab or FMT)&#xD;
May be related to ancillary CDI treatment&#xD;
Not related to ancillary CDI treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment IBS-like symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>Development of post-treatment irritable bowel syndrome like symptoms associated with bezlotoxumab treatment or FMT treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of antibiotic use</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eradication of toxigenic C. difficile</measure>
    <time_frame>3 and 12 weeks</time_frame>
    <description>As assessed by PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal microbiota (16S) alfa- and beta-diversity</measure>
    <time_frame>Pre-treatment and 3 and 12 weeks</time_frame>
    <description>As assessed by 16S rRNA amplicon sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>12 weeks</time_frame>
    <description>Costs per cured patient (global and sustained cure) and costs per QALY gained, using the EQ-5D-5L health questionaire that assesses five domains by 5 point scale, e.g. no/slight/moderate/severe/extreme impairment and a visual analogue 0-100 scale of health rating, higher is better)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient wellbeing</measure>
    <time_frame>Pre-treatment and 12 weeks</time_frame>
    <description>As assessed by questionnaire, that includes:&#xD;
self rated health - 5 point scale, higher is worse outcome&#xD;
happiness - 7 points scale, higher is worse outcome&#xD;
optimism - 6 items&#xD;
patient health questionnaire PHQ-9 - 9 items with 4 point scale, higher is worse outcome&#xD;
hospital anxiety and depression scale HADS - 14 items</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of patients with improved defecation pattern</measure>
    <time_frame>12 weeks</time_frame>
    <description>As assessed by personal diary</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Clostridium Infections</condition>
  <condition>Clostridioides Difficile</condition>
  <condition>Enterocolitis, Pseudomembranous</condition>
  <arm_group>
    <arm_group_label>Strategy A: initial SoC + bezlotoxumab. SoC + FMT rescue therapy.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>initial bezlotoxumab in addition to 14 days SoC oral antibiotic treatment with vancomycin 125 mg QID. 14 days of vancomycin 125mg QID plus fecal microbiota in case of treatment failure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Strategy B: initial SoC + FMT. Fidaxomicin rescue therapy.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fecal microbiota transplantation in addition to 14 days SoC oral antibiotic treatment with vancomycin 125 mg QID. 10 days of fidaxomicin 200 mg BID in case of treatment failure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bezlotoxumab</intervention_name>
    <description>single intravenous infusion of bezlotoxumab 10 mg/kg</description>
    <arm_group_label>Strategy A: initial SoC + bezlotoxumab. SoC + FMT rescue therapy.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation (FMT)</intervention_name>
    <description>single infusion of 198 cc fecal suspension (derived from 60g donor feces) via duodenal tube or coloscopy</description>
    <arm_group_label>Strategy B: initial SoC + FMT. Fidaxomicin rescue therapy.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin oral</intervention_name>
    <description>14 days vancomycin oral 125mg QID (250mg QID when 125mg not available)</description>
    <arm_group_label>Strategy A: initial SoC + bezlotoxumab. SoC + FMT rescue therapy.</arm_group_label>
    <arm_group_label>Strategy B: initial SoC + FMT. Fidaxomicin rescue therapy.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-90 years old&#xD;
&#xD;
          -  diarrhea (3 or more unformed stools per 24h for two consecutive days; or &gt;= 8 unformed&#xD;
             stools per 48h) XML File Identifier: KqQEbBLRYEZjGgsIl5GcI+NXCyM= Page 10/22&#xD;
&#xD;
          -  positive PCR test for toxin A/B genes and/or positive toxin EIA for current and&#xD;
             previous episodes (low PCR cycle threshold value when only PCR performed)&#xD;
&#xD;
          -  a minimum of two prior CDI episodes&#xD;
&#xD;
          -  previous episode is maximum of 3 months prior to the current episode&#xD;
&#xD;
          -  the current episode responds well to Standard of Care treatment (vancomycin or&#xD;
             fidaxomicin orally).&#xD;
&#xD;
          -  Assessment of the severity of the disease will be performed according to the ESCMID&#xD;
             recommendations.&#xD;
&#xD;
          -  Both mild and severe CDI will be included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe complicated CDI, i.e presence of: hypotension, septic shock, elevated serum&#xD;
             lactate, ileus, toxic megacolon, bowel perforation, or any fulminant course of&#xD;
             disease.&#xD;
&#xD;
          -  ICU admission for underlying disease&#xD;
&#xD;
          -  pregnancy or current desire for pregnancy&#xD;
&#xD;
          -  breastfeeding&#xD;
&#xD;
          -  (prolonged) use of antibiotics (other than for treatment of CDI) during the study&#xD;
             period or directly after the intervention&#xD;
&#xD;
          -  previous use of bezlotoxumab or fecal microbiota transplantation&#xD;
&#xD;
          -  a history of underlying congestive heart failure (potential safety signal phase-III&#xD;
             trail bezlotoxumab).&#xD;
&#xD;
          -  Diagnosis of inflammatory bowel disease in medical history.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J van Prehn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>J van Prehn</last_name>
    <phone>0031 (0)71 52 63931</phone>
    <email>j.vanprehn@lumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amsterdam University Medical Centers, AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>A Goorhuis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haaglanden Medical Center</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>J J Keller</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>J van Prehn</last_name>
    </contact>
    <investigator>
      <last_name>M MC Lambregts</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>E M Terveer</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>E J Kuijper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>E van Nood</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Joffrey van Prehn, MD, PhD</investigator_full_name>
    <investigator_title>Clinical Microbiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
    <mesh_term>Enterocolitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

